Cytosorbents Earnings Call Transcripts
Fiscal Year 2025
-
Record 2025 revenue was driven by international growth and new innovations, offset by German restructuring. Gross margin improved, cost reductions were implemented, and the company targets cash flow break even in H2 2026 while advancing DrugSorb-ATR FDA approval.
-
The discussion highlighted the company's regulatory and financial strategies, focusing on DrugSorb-ATR's U.S. approval pathway and the strong clinical need for blood purification in cardiac surgery. Subgroup analyses and European data support efficacy, with FDA approval targeted for mid-2026.
-
A platform blood purification technology is driving growth in critical care and cardiac surgery, with strong international sales and a focus on U.S. regulatory approval for a breakthrough device targeting bleeding in patients on blood thinners. Plans include a direct sales launch, expansion to new indications, and achieving cash flow breakeven in Q1 2026.
-
Q3 2025 revenue rose 10% year-over-year to $9.5 million, with gross margin improving to 70%. Strategic cost reductions and a restructured loan agreement support the goal of cash flow break-even by Q1 2026, while a new FDA submission for DrugSorb ATR is planned for early 2026.
-
CytoSorb and DrugSorb-ATR blood purification technologies are driving growth, with strong clinical evidence supporting reduced mortality and complications in critical care and cardiac surgery. Regulatory progress continues for DrugSorb-ATR in North America, while financial performance remains robust with high margins and expanding sales.
-
Q2 2025 saw 9% revenue growth year-over-year, driven by strong German and distributor sales, with gross margin steady at 71%. Regulatory appeals for DrugSorb-ATR are ongoing, with decisions expected in 2025, while CytoSorb continues to gain clinical validation in sepsis and cardiac surgery.
-
CytoSorbents presented strong sales growth for CytoSorb and detailed DrugSorb-ATR's regulatory path, with FDA and Health Canada decisions expected in 2025. Clinical data supports reduced mortality and bleeding, and the company aims for breakeven by late 2025 while preparing for a controlled U.S. launch if approved.
-
Q1 2025 revenue declined 3% year-over-year to $8.7M, with strong international sales offsetting German weakness. Gross margin remained solid at 71%, and operational improvements are moving the business toward break-even by late 2025. Regulatory decisions for DrugSorb ATR in the U.S. and Canada are expected this year.
Fiscal Year 2024
-
Q4 and full-year revenues grew strongly, led by international sales, with gross margins at 71%. Regulatory progress for DrugSorb-ATR continues, and the company is targeting near break-even for its core business by end of 2025, supported by improved liquidity and cost controls.
-
Q3 2024 saw 11% year-over-year product sales growth, improved margins, and reduced losses, with regulatory submissions for DrugSorb-ATR under review in the U.S. and Canada. Cash burn decreased, and the company is positioned for North American expansion pending 2025 approvals.
-
DrugSorb-ATR is set for FDA and Health Canada submission, targeting a $650M market for perioperative bleeding in CABG patients on Brilinta. CytoSorb's global reach, strong clinical data, and strategic partnerships position it as a leader in acute care blood purification.
-
Q2 2024 saw 5% revenue growth and a 48% reduction in operating loss, with strong gross margins and continued cost-cutting. Regulatory submissions for DrugSorb-ATR remain on track, and new product launches and market entries are driving growth.